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Abstract  16 
 17 
Introduction 18 
Chagas disease, the most important parasitic infection in Latin America, is caused by the intracellular 19 
protozoan Trypanosoma cruzi. To treat this disease, only two nitroheterocyclic compounds with toxic 20 
side effects exist and frequent treatment failures are reported. Hence there is an urgent need to develop 21 
new drugs. Recently, metabolomics has become an efficient and cost-effective strategy for dissecting 22 
drug mode of action, which has been applied to bacteria as well as parasites, such as different 23 
Trypanosome species and forms. 24 
Objectives 25 
We assessed if the metabolomics approach can be applied to study drug action of the intracellular 26 
amastigote form of T. cruzi in a parasite-host cell system.  27 
Methods  28 
We applied a metabolic fingerprinting approach (DI-MS & NMR) to evaluate metabolic changes induced 29 
by 6 different (candidate) drugs in a parasite-host cell system. In a second part of our study, we studied 30 
the impact of two drugs on polar metabolites, lipid and proteins to evaluate if affected pathways can be 31 
identified. 32 
Results  33 
The metabolic signatures obtained by the fingerprinting approach clustered according already described, 34 
similar mode of drug actions and that were different from three candidate drugs. Significant changes 35 
induced by drug action were observed in all the three metabolic fractions (polar metabolites, lipids and 36 
proteins). We identified a general impact on the TCA cycle, but no specific pathways could be attributed 37 
to drug action, which might be caused by a high percentage of common metabolome between a 38 
eukaryotic host cell and a eukaryotic parasite. Additionally, ion suppression effects due to differences in 39 
abundance between host cells and parasites may have occurred. 40 
Conclusion  41 
We validated the metabolic fingerprinting approach to a complex host-cell parasite system. This 42 
technique can potentially be applied in the early stage of drug discovery and could help to prioritize early 43 
leads or reconfirmed hits for further development.  44 
 45 
 46 
  47 
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1 Introduction  48 
Chagas disease, the most important parasitic infection in Latin America, is caused by the intracellular 49 
protozoan Trypanosoma cruzi. The nitroheterocyclic compounds benznidazole and nifurtimox are the 50 
only drugs available to treat T. cruzi infections. They have been in use for decades, despite a requirement 51 
for long administration periods (60-90 days), frequent reports of treatment failure and toxic side-effects 52 
(Gaspar et al., 2015; Molina et al., 2014; Morillo et al., 2015; Morillo et al., 2017; Wilkinson and Kelly, 53 
2009). Both compounds are pro-drugs and are activated within the parasite by the mitochondrial 54 
nitroreductase, TcNTR-1 (Mejia et al., 2012; Wilkinson et al., 2008), giving rise to reactive metabolites 55 
that have trypanocidal activity. In the case of benznidazole, these metabolites are highly mutagenic and 56 
can cause widespread damage to genomic DNA (Campos et al., 2017).  57 
The urgent need to develop new drugs against Chagas disease is being tackled at an international level 58 
by large multidisciplinary teams (Chatelain, 2017; Katsuno et al., 2015) , with expertise from both the 59 
academic and commercial sectors. The main approach involves high-throughput phenotypic screening of 60 
large compound libraries, followed by downstream lead optimization studies including target 61 
deconvolution and identification of potential resistance mechanisms. Recently, metabolomics has 62 
become an efficient and cost-effective strategy for dissecting drug mode of action (MoA) (Zampieri et al., 63 
2018). Metabolic perturbations induced by drug activity can be detected as a change in the metabolome, 64 
since small molecules are downstream products of biological changes. Even if the drug target is not 65 
directly metabolic, specific changes in the metabolome can be observed (Zampieri et al., 2018). NMR 66 
spectroscopy and mass spectrometry (MS) have been applied to predict drug mode of action (MoA) of 67 
antibiotics (Halouska et al., 2012; Zampieri et al., 2018). Based on the same technology we developed an 68 
automated screening method for bacteria, Met-SAMoA® (Metabolic screening of antimicrobial mode of 69 
actions). The approach is based on the comparison of the metabolic signatures induced by drugs with 70 
known MoA and to new drug candidates. Antibiotics are available covering different MoA, but also 71 
different drugs with the same MoA, which allows the construction of a robust database. Studying 72 
metabolic changes induced by drugs has also been applied to parasites and more specifically to 73 
trypanosomes. The effect of nifurtimox and pentamidine on T. brucei (Creek et al., 2013; Vincent et al., 74 
2012) and of benznidazole on T. cruzi (Trochine et al., 2014) has been investigated. In comparison to 75 
bacteria, studying trypanosomes adds an extra difficulty because the parasite exists in different forms 76 
between insect vector and host. Metabolomic studies have been performed on the isolated bloodstream 77 
typomastigotes for T. brucei and on epimastigotes, the insect vector form of the parasites, for T.cruzi. 78 
The amastigote form of T. cruzi, however, has not been investigated with a metabolomics approach. 79 
Studies of antimalarial drugs against Plasmodium falciparum in red blood cells, however, have been 80 
performed (Allman et al., 2016; Cobbold et al.,2016). 81 
Since we were interested in drugs that are effective against the intracellular amastigote form of T. cruzi, 82 
we studied a complex system, host cells infected with parasites. We employed a metabolic fingerprinting 83 
approach (direct injection (DI)–HRMS and NMR) to analyse this system treated under different anti-84 
parasitic drug treatment conditions. Since only two drugs, with overlapping MoAs, are in use for 85 
treatment against Chagas disease, the number of compounds with known MoA is limited and hence a 86 
robust database construction for a screening approach is not yet possible. The objective of this study was 87 
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to test if we can obtain metabolic signatures of drugs in a complex host cell – parasite-system, relative to 88 
their MoA. We tested the reference drugs and experimental drugs, which might have different MoA. In 89 
the second part of our study, we applied a more comprehensive metabolomics, lipidomics and 90 
proteomics approach to evaluate if metabolic changes induced by drug action can be attributed to a 91 
specific metabolic fraction or if they can be correlated to a particular pathway. We show here that the 92 
fingerprinting approach  can be successfully applied to study different drugs in a complex host cell-93 
parasite system. Furthermore, we demonstrate  that comprehensive metabolomics and proteomics 94 
reveal metabolic differences relative to drug action, but interpretation towards affected pathways 95 
remains challenging due to the common metabolome of a eukaryotic parasite in a eukaryotic host cell.  96 
2 Materials and methods  97 
An overview of the applied experimental strategies is presented the supplementary materials Error! 98 
Reference source not found., as well as a detailed description of the cell culture preparation, sample 99 
preparation, NMR and LC-HRMS experiments.  100 
2.1 Cell culture and sample collection 101 
2.2 The L6 rat myoblast cell line (L6.G8.C5 (ECACC 92121114)) and T. cruzi clone CL Brener 102 
(DTU VI) were used as the infection model. L6 cells were grown to 70 % of confluence 103 
and infected with trypomastigotes at a ratio of 10 parasites per myoblast cell for 16 104 
hours. After removal of extracellular parasites, rat myoblasts were incubated for 48 105 
hours to establish infection. Subsequently, cultures were treated with 6 different drugs 106 
(benznidazole, nifurtimox, posaconazole, S205, S448 and S1000) at their respective 107 
IC50 concentrations and infected and uninfected treated cultures were kept in parallel 108 
as controls. The DMSO concentration was adjusted to 0.125% in all the conditions. 109 
Since a direct cell count is not possible for each well, we estimate the typical infected 110 
untreated samples to have had ~4.8 x 105 L6 cells, ~10% of them infected and the 111 
average number of amastigotes per infected cell would have been approximately 8 and 112 
16 for the 24 hr and 48 hr time points respectively.For the fingerprinting experiments, 113 
five replicates after 24 h and 48h of treatment were prepared. For the profiling 114 
experiments were performed with ten replicates after 24 h of treatment with two 115 
drugs. At the end of incubation time, medium and cells were separated, cells were 116 
washed, quenched and detached with cold methanol/ water (50/50, v/v) and snap 117 
frozen in liquid nitrogen and stored at -80°C until further processing. Methanol/ water 118 
(50/50) was described by Sapcariu et al. (2014) as suitable solvent to detach adherent 119 
cells. Furthermore, own tests showed that it was well suited and allowed to process a 120 
high quantity of samples in a short time. Sample preparation  121 
For the metabolic fingerprinting experiments, culture supernatants were prepared for NMR analysis to 122 
obtain the extracellular metabolome and the cellular lysate in methanol/ water (50/50, v/v) were used 123 
for DI-MS analysis to obtain the intracellular metabolome.  124 
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For the metabolic profiling experiments the supernatant samples were prepared for NMR analysis. 125 
Myoblast cells were extracted with a modified Folch method (Folch et al., 1957) to obtain three fractions 126 
of the intracellular metabolome: proteins, polar metabolites and lipids. Protein analysis was performed 127 
using a bottom-up approach, by proteolytic digestion of proteins with trypsin prior to LC-MS/MS 128 
analysis.  129 
2.3 NMR and mass spectrometry data acquisition 130 
The extracellular metabolite spectra for the fingerprinting, the extracellular and the intracellular polar 131 
fraction for the metabolomics approach  were acquired by NMR. A one dimensional proton spectrum 132 
was acquired at 298K using a 600 MHz Avance III HD NMR from Bruker, equipped with quadruple 133 
cryogenic inverse probe for 1H/13C/15N/31P detection. For the fingerprinting approach, intracellular 134 
metabolite spectra were obtained by direct infusion high resolution mass spectrometry (DI-HRMS) on a 135 
Q-Exactive mass spectrometer (Thermo Scientific) coupled to a Dionex Ultimate 3000 liquid 136 
chromatography chain (Thermo Scientific). The mass spectrometer was operated in positive mode at 137 
3.5kV, at a resolution of 140 000.  138 
For the profiling approach the intracellular lipids and proteins were analyzed by LC-HRMS. Lipids were 139 
separated on an Xselect CSH C18 column (1 x 150 mm, 3.5µm i.D.) using water/acetonitrile (80/20, v/v) 140 
as solvent A, isopropanol/acetonitrile/water (88/10/2) as solvent B. Two separate injections were 141 
performed to acquire spectra in positive and negative ionization modes. Data were acquired in full scan 142 
alternating with data dependent acquisition (top 5) to obtain MS/MS spectra. For the proteomics 143 
analysis, capillary LC-MS/MS analysis was performed using an ultimate 3000 RS system (Themo Scientific) 144 
coupled to a Q-TOF Maxis HD mass spectrometer (Bruker Daltonics) operating in positive mode. Samples 145 
were pre-concentrated on a C18 µ-precolumn (300 µm i.d. x 5 mm Acclaim PepMap) and subsequently 146 
separated on a C18 capillary column (300 µm inner diameter x 15 cm, acclaim PepMap RSLC, Thermo 147 
Scientific) with H2O/ACN 98/2 (v/v) as solvent A and ACN as solvent B, both containing 0.1% formic 148 
acid.The Maxis HD mass spectrometer was operated using the Instant Expertise data acquisition mode 149 
(self-optimizing MSMS acquisition) selecting up to sixteen of the most intense multiply charged ions (2+, 150 
3+ and 4+) for MS/MS analysis. For both, lipid and proteins, quality control samples were used to 151 
monitor the analytical variability along the runs.  152 
2.4 Data processing  153 
NMR and DI-MS data were preprocessed with an in-house workflow developed in Matlab to extract 154 
metabolic features. Quantification of relevant metabolites detected by NMR was performed using the 155 
Chenomx NMR suite 8.31 (Alberta, Canada). The Chenomx database was completed with new 156 
metabolites for those which were missing from original one using the compound builder module. 157 
Extraction and alignment of LC-MS spectra issued from lipid and protein analysis were performed using 158 
OpenMS (v. 2.1.0) software and in-house solutions developed with Matlab. QC samples were used to 159 
correct analytical drifts within and between batches. Features that were not present in 80% in the 160 
defined groups (QCs and the different tested conditions) were considered as unstable and were 161 
removed. Additionally, lipids features with a CV greater than 20% in QC samples were removed and 162 
correlated and co-eluting features from positive and negative mode were grouped to form putative 163 
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compounds. No normalization of the biomass was applied, because the biomass of the parasites was 164 
estimated to be 400-times lower compared to the myoblasts and hence a protein determination would 165 
not detect differences. The average volume of a T.cruzi amastigote was estimated to 14.5 fL (Rohloff et 166 
al., 2003) and we estimated the volume of myoblasts to 6.5 pL, based on the average size of 23 µm of 167 
spherical detached myboblasts. Since the infection rate of the myoblasts is about 10% with 8 and 16 168 
parasites per myoblast after 24h and 48h respectively, we estimate the volume ratio parasites to 169 
myoblasts to 1: 450 after 24h and 1:420 after 48h and hence this difference in biomass negligible. The 170 
sum of all the signal intensities showed no difference in NMR and for the lipids 15% difference between 171 
infected and uninfected condition, but no differences between with and without treatment. After 172 
statistical analysis, relevant putative compounds were identified using the LipidMatch software (Koelmel 173 
et al., 2017). Identification levels are reported according to the Metabolomics standard initative (Sumner 174 
et al., 2007). Proteins were identified prior to statistical analysis via the Mascot server using the curated 175 
Uniprot databases Rattus norvegicus (8,036 sequences) and Trypanosoma cruzi (126 sequences). 176 
Identifications were validated when two peptides with a minimum length of 5 amino acids were 177 
detected and a false discovery rate of 5% was applied.  178 
2.5 Statistical analysis  179 
Discriminant analyses were performed using supervised multivariate analyses with the partial least 180 
square (PLS) algorithm (Barker and Rayens, 2003; Wold et al., 2001). Subsequently, the coefficient of 181 
correspondence R2 and the cross-validation coefficient of correspondence Q2 were computed to 182 
evaluate the model performance. For the fingerprinting approach, the elastic net algorithm was used to 183 
select the most discriminant variables (Clemmensen et al., 2011) to compare the signatures between 184 
different drugs via Venn Diagrams. In the profiling experiments, for the lipids and proteins, the 100 most 185 
important variables were selected and subsequently univariate differential analysis was performed to 186 
identify relevant metabolites (p < 0.05). For the polar metabolites, identification and quantification was 187 
performed prior to univariate differential analysis. Furthermore, z-scores were calculated to regulation 188 
direction. Positive and negative z-scores mean up- and down-regulations, respectively. 189 
3 Results & discussion  190 
3.1 Metabolic fingerprinting approach  191 
The aim of the fingerprinting approach was to test if rat myoblasts infected with T. cruzi, and treated 192 
with different drugs, can be discriminated by their metabolic signatures. Infected rat myoblasts were 193 
incubated with six different drugs at their respective IC50 for either 24 or 48 hours. The selected agents 194 
included two reference drugs (benznidazole and nifurtimox), the candidate compound posaconazole, 195 
and three experimental drugs (S205, S448 and S1000). Extracellular metabolic signatures were obtained 196 
by NMR spectroscopy and intracellular signatures by DI-HRMS. The data were subjected to PLS analysis 197 
to test if metabolic signatures specific to each drug treatment could be identified (Error! Reference 198 
source not found.). For the intracellular metabolome, three different clusters were observed after 24 199 
and 48 hours drug treatment, whereas the extracellular metabolome showed the same clusters only 200 
after 48 hours treatment. The signatures of benznidazole and nifurtimox form one group, the three 201 
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experimental drugs (S205, S448, S1000) form another, and Posaconazole is separated from the other two 202 
groups. Of the six drugs tested, the MoA for three of them has been described. Benznidazole and 203 
nifurtimox are pro-drugs that are activated by the parasite nitroreductase TcNTR-1, to generate nitro-204 
species that react with the nucleic acids, causing significant DNA damage (Hall et al., 2011; Hall and 205 
Wilkinson, 2012). Posaconazole is an ergosterol biosynthesis inhibitor that blocks growth since ergosterol 206 
is required for parasite membranes (Lepesheva et al., 2010). The results of the PLS analysis reflected the 207 
differences and similarities between the three drugs, with separation of poscaconazole from the 208 
benznidazole-nifurtimox-cluster. Our results also suggest that the three experimental drugs have a MoAs 209 
distinct from the three reference drugs and that their MoAs may be similar, relatively to benznidazole, 210 
nifurtimox and posaconazole.  211 
To test if specific signals for each drug treatment could be obtained, PLS analysis of the infected 212 
myoblasts and the infected, treated myoblasts were performed for each drug separately. The results are 213 
presented in figures Error! Reference source not found. and Error! Reference source not found.. Despite 214 
visual separation was obtained, the obtained Q2 –values, which represent the predictive power of a 215 
model obtained by cross-validation, are not satisfactory for the majority of the tested conditions (< 0.75). 216 
A variable selection using the elastic net algorithm was performed to remove features not relevant for 217 
the model. The selection was performed with 1, 5, 10, 20, 50, 100, 150, 300, 400 and 600 variables. Of all 218 
the models, the best Q2-values were obtained between 50 and 100 variables and model performance 219 
was decreasing with increased number of variables (Table Error! Reference source not found.). Both, 220 
intra- and extracellular metabolome allowed discrimination of each drug treatment from the control 221 
after both 24 and 48 hours treatment (Q2 >0.85). Since both treatment time points enabled metabolic 222 
signatures to be obtained, we choose 24h of treatment for the subsequent profiling experiments 223 
because after 48 h of treatment the myoblasts are close to cell death and we want to avoid unspecific 224 
death signatures. Furthermore, the drugs benznidazole and S205 are separated after 24 h in the 225 
extracelluar medium and this are the drugs which are further investigated.  226 
3.2 Profiling approach  227 
3.2.1 Global, supervised statistical analysis  228 
The aim of this comprehensive profiling approach, covering polar metabolites, lipids and proteins, was to 229 
test if metabolic changes induced by the drug treatment can be attributed to a specific fraction of the 230 
metabolome and if pathways affected by the drugs can be identified. Next to the treatment of the 231 
infected myoblasts with the drugs, we also treated the uninfected myoblasts to test if we can detect an 232 
impact of the drug on the host cell. We focused on benznidazole as reference drug and the S205 as 233 
experimental drug. In total six conditions were prepared: 1) infected myoblasts (cInf), 2) infected 234 
myoblasts treated with benznidazole (cInfBz), 3) infected myoblasts treated with S205 (cInfS2), 4) 235 
uninfected myoblasts, (cUnInf) 5) uninfected myoblasts treated with benznidazole (cUnInfBz) and 6) 236 
uninfected myoblasts treated with S205 (cUnifS2). Twenty-four hours after the initiation of treatment, 237 
culture medium and cells were separated. From the cell culture medium (extracellular metabolome), 238 
only polar metabolites were studied. Cells were processed to obtain three different intracellular 239 
fractions: polar metabolites, lipids and proteins. Polar metabolites were analyzed by NMR, lipids and 240 
proteins by LC-HRMS. Supervised statistical analysis (PLS) was performed with the extracted features and 241 
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the results are shown in Error! Reference source not found.. The strongest separation was observed 242 
between the infected and uninfected conditions for all metabolic fractions, which might be caused by 243 
the metabolome of the parasite and related changes of the myoblast metabolism. Unlike lipids and 244 
proteins, extracellular polar metabolites also clustered according to all the tested conditions (Error! 245 
Reference source not found.A). The cUnInfS2 condition clusters closely with cUnInf, indicating that the 246 
impact on the polar metabolome of S205 is limited, whereas cUnInfBz forms a separate group, indicating 247 
a higher impact on the host cell metabolome. For the intracellular, polar metabolome (Error! Reference 248 
source not found.B), the clusters are less pronounced, probably due to the lower signal intensity, close 249 
to the limit of detection compared to the extracellular metabolome (Figure Error! Reference source not 250 
found.). In PLS analysis of intracellular lipids (Error! Reference source not found.C) cInfS2 showed a 251 
separate group, whereas cInfBz shows some overlap with cInf. No separation subgroups could be 252 
observed for the uninfected conditions, indicating that the impact of the two drugs on the host lipidome 253 
is limited. Also the impact of the two drugs on the proteome of the host cell seems limited; no clusters 254 
were observed for the uninfected conditions (Error! Reference source not found.D). Interestingly, in the 255 
PLS analysis of the proteome (Error! Reference source not found.D), cInfS2 is clustered together with 256 
the non-infected conditions which shows that the proteome becomes similar to cUninf. 257 
The impact of the drugs on the uninfected host cells was limited, except for the polar metabolome after 258 
benznidazole treatment, which is coherent with the unspecific radical mechanism described for this drug 259 
(Hall et al., 2011; Hall and Wilkinson, 2012). According to internal data S205 had low cytotoxic effects on 260 
cell lines, which is in line with our results showing a low impact on the metabolome. In order to 261 
investigate more precisely the changes induced during the treatment of infected myoblasts with the 262 
drugs, we performed statistical analysis and identification of the underlying features for each of the 263 
three fractions separately. Due to low signal intensities of the intracellular polar metabolome by NMR 264 
analysis, the data were not considered for further analysis. 265 
3.2.2 Extracellular polar metabolite markers  266 
To determine pathways that are affected by the drug treatment, PLS models were calculated by 267 
comparing the infected condition with the infected treated condition for the two drugs separately. 268 
Metabolite concertations were quantified with the help of Chenomx NMR suite 8.31 software using 269 
internal standard reference DSS. Then, univariate analysis was performed for the different treatments to 270 
determine most relevant metabolites. Table Error! Reference source not found. shows the metabolites 271 
that are were significant in at least one of the conditions. For the treatment with S205, glucose and the 272 
metabolites of the TCA cycle pyruvate, citrate, succinate and acetate are clearly affected. For 273 
benznidazole only lactate levels are altered. The concentrations of glucose, TCA cycle metabolites and 274 
threonine are plotted in Error! Reference source not found. in order to understand if the drug acts on 275 
the host, amastigotes or both of them. Glucose consumption tends to be higher in the infected cInf, 276 
cInfBz and cInfS2 compared to the uninfected cUnInf, cUnInfBz and cUnInfS2 conditions, but high 277 
variations are observed. Only cInfS2 compared to cInf myoblasts has significantly lower glucose 278 
consumption and it seems to be similar to cUnInfS2 cells. The glycolysis metabolite pyruvate excreted in 279 
culture media in infected cInf and cInfBz conditions is lower compared to uninfected cUnInf and cUnInfBz 280 
counterparts, which could be explained by integration of this metabolite in parasite pathway. The 281 
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pyruvate level in cUnInf and cUnInfS2 is the same, while in cUnInfBz it is lower. This suggests that, unlike 282 
S205, benznidazole affects the host metabolism contrary, which is in agreement with the global PLS 283 
analysis. As for S205, the pyruvate level in the cInfS2 condition is significantly higher compared to cInf, 284 
similar to the uninfected conditions, and it looks like the metabolization of pyruvate by parasite is lower. 285 
Similar finding could be observed for other TCA related metabolites lactate and citrate. Indeed, in cInfS2 286 
condition these metabolites levels are normalized and closer to the uninfected conditions than cInf. 287 
Similarly, S205 tends to decrease acetate level compared to infected conditions cInf or cInfS2, but the 288 
effect is more limited and far from normalization.  289 
Surprisingly, we can observe a completely opposite effect of S205 in the TCA cycle on succinate. Its level 290 
in cInfS2 compared to cInf is approximately 2-fold higher, when in the uninfected condition this excreted 291 
succinate is absent. The production of succinate during infection could be a host response as well as a 292 
metabolic activity of the parasite. Indeed, it is known that heart cells under hypoxic stress can produce 293 
high amounts of succinate (Chouchani et al., 2014) Trypanosomatids themselves may produce about 294 
60% of all excreted succinate within glycosomes by NADH-dependent fumarate reductase (Besteiro et 295 
al., 2002). Interestingly, accumulation of succinate was also observed in vivo for T. cruzi infected mice in 296 
heart tissue (Girones et al., 2014). However, for the increased accumulation of succinate in the cInfS2 297 
condition, compared to the infected untreated condition,  we cannot distinguish if this is due to drug 298 
action on the parasite or if it is an indirect effect of the parasite or host cell. Only the use of labelled 299 
glucose could help understand the underlying mechanisms, as labeling of the resulting succinate would 300 
be differnt depending on its glycosomal or mitochondrial origin (Besteiro et al., 2002; van Weelden et al., 301 
2003). Finally, looking at amino acids that have been observed as discriminant, the amount of threonine  302 
in all infected conditions was completely depleted (Error! Reference source not found.). Similar data 303 
were found for Trypanosoma brucei (Millerioux et al., 2013) and actually, threonine is known to be the 304 
fastest amino acid to be metabolized by parasite for lipid biosynthesis. Glycine follows a different 305 
pattern, with a slight but significant increase during infection. However, even if global PLS models have 306 
identified these metabolites as significant in response to treatment, quantitative univariate results are 307 
less clear on the impact of the drugs. It enlightens the differences between global models and targeted 308 
approaches. Indeed, it shows that global models are able to identify subtle impact on some metabolic 309 
pathways that are not easily observed with targeted methods. While we observed variability due to 310 
biological batch effect between fingerprinting experiment and profiling one, for example threonine 311 
degrades slower than in the first compared to the second experiment. Generally acetate, glycine, 312 
pyruvate, lactate show the same trends in both experiments (data not shown) proving the 313 
repeatability and the consistency of experimental data.  314 
3.2.3 Lipid markers  315 
The most pronounced separations in the global PLS model were investigated in more detail to determine 316 
pathways affected by infection and drug treatment. The selection of the 100 most important variables s 317 
was performed for the following models: A) cInf vs cUnif, B) cInf vs cInfBz, C) cInf vs cInS205 and D) 318 
cInfBz vs cInfS2. Subsequently, the variables which represent putative compounds were identified using 319 
the LipidMatch workflow (Koelmel et al., 2017) and all non-identified compounds were removed. The 320 
main lipid classes that were identified are: phosphatidylethanolamines (PE), phosphatidylcholins (PC), 321 
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oxidized PC and PE, Lyso-PE (LPE) and lyso-PC (LPC), the plasmalogens with PE- and PC-head groups and 322 
the sphingolipids (SL) ceramides and sphingomyelin. Identified lipids showing significant differences (p 323 
<0.05) between the peak areas in the different models are presented in Table Error! Reference source 324 
not found.. Furthermore, z-scores indicate the up- and down regulation in each of the conditions.  The 325 
highest number of significantly different lipids was found for the model cInf vs cUnif. Twelve LPE and LPC 326 
differentiate infected from uninfected myoblasts as they are more abundant in the infected condition. 327 
This effect of the infection is in accordance with results of Gazos-Lopes et al. (2014), who identified LPC 328 
C18:1 as a platelet aggregation factor that is observed in myocarditis, whereas LPC with different chain 329 
length  did not show this effect. Furthermore, 15 glycerophospholipids, mainly PCs, discriminated the 330 
infected from uninfected myoblasts which were all less abundant in the infected compared to the 331 
uninfected condition. Oxidated PCs and PEs also contribute to the separation of the conditions, but no 332 
clear up- or down regulation could be observed. Additionally, identifications are based on exact mass 333 
only and are hence not very precise due to high overlap of exact masses. Plasmalogens are positively and 334 
negatively correlated with infection and no coherence among head groups, fatty acid chains, alkyl- or 335 
alkenyl- linkage could be identified. Plasmalogens are abundant lipids in heart tissue (Braverman and 336 
Moser, 2012) and changes in this abundant lipid class might be related to remodeling of some lipid 337 
chains by T.cruzi. It was shown that T.cruzi incorporates host-glycerophospholipids by changing specific 338 
fatty acid chains (Gazos-Lopes et al., 2017). The only two lipids that are only significant in the drug 339 
treatment condition (models B, C and D) and not in the control (model A) belong to the class of SL, more 340 
specifically a SM and a ceramide. Identification levels are not precise for this two lipids, hence no further 341 
conclusions can be drawn. Lipids are considered as targets for novel drug therapies against 342 
trypanosomatids since they exhibit critical functions, from building blocks of biological membranes to 343 
signal transduction, energy storage and virulence. In order to target the parasite the identification of 344 
unique lipid species or metabolic pathways is required (Biagiotti et al., 2017). Guan and Maser (2017) 345 
characterized the sphingolipidome of different trypanosome species and identified 346 
aminoethylphosphonate ceramide and Inositolphosphoryl ceramide. The SL ceramides and SM we 347 
identified that discriminated between both treatments are, however, not specific to the parasite, but 348 
ceramides are precursors of parasite specific SL (Guan and Maser, 2017). SL have been described as 349 
being affected by drug treatment of trypanosomatids: Stoessel et al. (2016) identified an accumulation 350 
of ceramides in the bloodstream form of T. brucei after treatment with OXPA (3-(oxazolo[4,5-b]pyridine-351 
2-yl)-anilide).  352 
 353 
3.2.4 Protein markers 354 
In order to investigate the proteins that explain the separations observed in the global PLS analysis 355 
(figure 2) more in detail, we performed univariate analysis on the following models: cInf vs cUnInf, cInf vs 356 
cInfBz, cInf vs cInfBz and cInfBz vs cInfS2. Only proteins that have a p-value less than 0.05 were kept for 357 
data mining and are listed in Table Error! Reference source not found.Error! Reference source not 358 
found.. The highest number of significantly different proteins was found for the model cInf vs cUnInf, in 359 
agreement with the lipidomics data. In cInf, host cell proteins (rattus norvegicus) that are involved in the 360 
glycolysis pathway (e.g. G6PI, KPYM) and de novo lipid synthesis (e.g. ACLY) are more abundant than in 361 
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the UnInf condition. This is in agreement with the polar metabolites results showing that infected cells 362 
consume more glucose than uninfected cells, and with data published by Shah-Simpson et al. (2017). The 363 
authors showed that T. cruzi amastigotes capitalize on the increase in glucose uptake by the infected 364 
cells to fuel their own metabolism and replication in the host cytosol. Interestingly, in S2-treated cells 365 
(model Inf-InfS205, table S8) the amount of G6PI enzyme go back down to the regular cell level as the Z 366 
score is similar to the uninfected cells (model Inf-Uninf, table S8 with Z scores at 2.8 and 2.7, 367 
respectively).From the protein list generated, and independently of the models, the first observations 368 
that we made was that only five proteins from T. cruzi were identified, two cytoskeleton proteins (TBB 369 
and TBA), the glycosomal D-glyceraldehyde-3-phosphate dehydrogenase (G3PG), the Ubiquitin-60S 370 
ribosomal protein L40 (RL40) and the mitochondrial Chaperonin HSP60 (CH60). There are two reasons to 371 
explain this observation; first we used the T. cruzi curated Swissprot database which contains 60 times 372 
less proteins than the Rattus norvegicus curated Swissprot database, and second, there is a high dynamic 373 
range between proteins of the host and those of the parasite. Myoblast proteins constitute the majority 374 
of abundant proteins that suppress identification of potential co-eluting peptides of T. cruzi during the 375 
LC-MS/MS runs. Amounts of these five proteins of T. cruzi in each condition tested, are shown in Error! 376 
Reference source not found.4. To confirm that peptides used for protein label-free quantitation are not 377 
shared between both eukaryotic organisms, myoblasts and parasites, we also performed the 378 
quantitation of the T. cruzi proteins for the uninfected conditions. As expected, no significant amount of 379 
T. cruzi proteins were observed for all the uninfected conditions tested. Therefore, we indeed used only 380 
unique peptides to specifically quantified proteins of T. cruzi. We observed significant differences for all 381 
of the five T. cruzi proteins only between infected cells (cInf) and infected cells treated with the S205 382 
drug. Unlike the S205 drug, when infected cells are treated with Benznidazole, only two of the five T. 383 
cruzi proteins are significantly different (TBB and G3PG) compare to the infected cells. Altogether, these 384 
results might suggest that the S205 drug is more efficient than benznidazole to clear the parasites out of 385 
the infected cells, in agreement with the global PLS shown in Error! Reference source not found.. It has 386 
to be noted that for both TBB and CH60 proteins the difference between cInf and cS2inf is highly 387 
significant (p-value < 0.001). Unlike the CH60 protein, the TBB protein also show significant difference 388 
between cInf and cBzinf. We may propose two hypothesis, either these observations reflect parasite 389 
killing as we don’t know the number of live parasites after the course of S205 treatment compare to 390 
untreated cells, or  it might suggest that the S205 drug affects pathways that are involved in the stress 391 
response of the parasites. Like CH60, but to a lower extent, the ubiquitin-60S ribosomal protein L40 also 392 
shows significant difference only in infected cells treated with the S205 drug, but not with benznidazole. 393 
Again, that might suggest that treatment with S205 affects pathways involved in the regulation of 394 
protein translation or it might reflect parasites killing, as previously noted. 395 
4 Overall discussion and conclusions  396 
The objective of this study was to test if we can obtain metabolic signatures of drugs in a complex host 397 
cell – parasite-system. We showed in our first approach, the fingerprinting, that screening for metabolic 398 
differences after drug treatment is possible in a complex system of two eukaryotes. The two reference 399 
drugs with known MoA showed signatures that were different from a candidate drug and three 400 
experimental compounds in development. Both intra- and extracellular metabolome are suitable to 401 
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obtain these signatures. Hence, we validated the approach already applied to bacterial cultures and 402 
parasite cultures in isolation to a complex system of two eukaryotes. Today, the number of drugs 403 
available to treat Chagas disease is limited, hence a construction of a robust database and a prediction of 404 
MoA, is not yet possible. However, the construction of such a database during the development of new 405 
drugs would be relevant. It could accelerate drug research in Chagas disease, since compounds with 406 
potentially new MoA could be identified in an early stage based on differences of metabolic signatures. 407 
This technique can potentially be applied in the early stage of drug discover and could help to prioritize 408 
early leads or reconfirmed hits for further development.  409 
In the second part of our study, we applied a more comprehensive metabolomics, lipidomics and 410 
proteomics approach to evaluate if metabolic changes induced by drugs can be attributed to a specific 411 
metabolic fraction or to common pathways. As for the fingerprinting, multivariate statistical analysis 412 
allowed the separation of the different conditions in all three fractions. Subsequent identification of the 413 
metabolites, lipids and proteins that are underlying these separations showed a strong impact of the 414 
infection. The majority of the metabolites and lipids that explain differences between infection and 415 
treatment are also discriminant for the infection only. The few metabolites and lipids that were only 416 
discriminant in the treated condition are metabolites that are in common between the host cell and the 417 
parasite, hence it is difficult to form hypothesis about pathways affected since we can’t distinguish 418 
between host cell and parasite. The fact that we studied a eukaryotic parasite in a eukaryotic host cell is 419 
likely to be responsible for this high overlap. However, we are able to identify that S205 has an impact 420 
on, or close to, the TCA cycle from the parasite and/or the host and that it has a more focused action on 421 
the metabolism compared to benznidazole. Lipids that were described as specific for T. cruzi in the 422 
isolated and extracellular form of the parasite were not detected in our study. In the proteomics 423 
approach, the number of proteins attributed to the rat myoblasts was 60-times higher than the number 424 
of proteins attributed to T. cruzi. The databases used for identification also contain 60 times more rat 425 
than parasite proteins, which explains these differences. Furthermore, rat myoblasts were more 426 
abundant in the extracted samples compared to T. cruzi, hence parasite specific lipids and proteins might 427 
be masked by ion suppression in mass spectrometry. The isolation of the intracellular form of the 428 
parasite from the host cell after cultivation, as it was performed by Gazos-Lopes et al. (2017), would be a 429 
possibility to overcome this ion suppression problem and allows to lower the limits of detection, but it is 430 
much more laborious than our approach. Separation of the two species, would also allow to attribute 431 
changes in metabolites that are common between the host cell and the parasite to one of the two and 432 
allow more mechanistic insights of the drug action. As a screening approach, however it is not suitable. 433 
The magnetic purification of Plasmodium falciparum parasites from red blood cells was chosen by Allman 434 
et al. (2016) to study the mode of action of antimalarial drugs using a targeted metabolomics approach. 435 
The authors detected much higher fold-changes after purification of parasites compared to bulk 436 
extraction of infected and uninfected red blood cells. This approach allows a higher throughput than a 437 
manual isolation. Our results and the two studies show that separation of the two species seems 438 
necessary to obtain pathway information.   439 
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